Gene And Cell Therapies In Asia: Can China Deliver Despite Murky Regulations?
Executive Summary
The first country ever to approve a gene therapy, China has subsequently lagged in the area due to a lack of clear regulatory pathways and insufficient financial incentives. Now a new crop of developers are aiming to revitalize ambitions and make the country a major power for promising novel treatments for rare neurodegenerative conditions, retinal dystrophy, HIV and cancer.
You may also be interested in...
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics
South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.
Gene And Cell Therapies In Asia: Indian Environment Evolving But Multiple Issues Unresolved
India has taken strides towards creating a supportive environment for its nascent gene therapy research, but the R&D and regulatory infrastructure is still evolving amid concerns over potential product costs.